Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Conservative Site-specific Recombination and Phase Variation

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adversarial Robust Federated Learning for Secure Mortality Risk Prediction using Multi-Institutional Electronic Health Records (EHRs).

Journal of visualized experiments : JoVE·2026

Same author

ISGylation is disrupted by <i>UBA7</i> gene variants identified in individuals with neurodevelopmental disorder phenotypes.

iScience·2026

Same author

Respiring cultureware for high-density, scalable, multipurpose cell-based bioproduction.

Research square·2026

Same author

Integration of Genome and Epigenetic Testing in the Diagnostic Evaluation of Developmental Delay: Differentiating Börjeson-Forssman-Lehmann (BFLS) and White-Kernohan (WHIKERS) Syndromes.

Genes·2025

Same author

Pathogenic de novo variants in PPP2R5C cause a neurodevelopmental disorder within the Houge-Janssens syndrome spectrum.

American journal of human genetics·2025

Same author

De novo variants in RYBP are associated with a severe neurodevelopmental disorder and congenital anomalies.

Genetics in medicine : official journal of the American College of Medical Genetics·2025

Search research articles

Related Experiment Video

Updated: Jun 30, 2025

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

Published on: May 22, 2020

Nuclease-free precise genome editing corrects MECP2 mutations associated with Rett syndrome.

Swati Bijlani¹, Ka Ming Pang¹, Lakshmi V Bugga¹

¹Department of Surgery, Beckman Research Institute of the City of Hope, Duarte, CA, United States.

Frontiers in Genome Editing

|March 18, 2024

Summary

Gene therapy for Rett syndrome successfully corrected MECP2 gene mutations using nuclease-free homologous recombination. This durable genome editing strategy offers potential for treating this neurodevelopmental disorder.

Keywords:

MeCP2 Rett syndrome adeno-associated virus genome editing homologous recombination

More Related Videos

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome

Published on: March 2, 2018

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

Published on: May 22, 2019

Related Experiment Videos

Last Updated: Jun 30, 2025

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

Published on: May 22, 2020

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome

Published on: March 2, 2018

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

Published on: May 22, 2019

Area of Science:

Genetics
Neuroscience
Molecular Biology

Background:

Rett syndrome is a progressive neurodevelopmental disorder caused by mutations in the MECP2 gene.
Gene therapy for Rett syndrome is challenging due to strict expression level requirements.
Previous approaches like ectopic expression have unknown durability.

Purpose of the Study:

To evaluate a nuclease-free homologous recombination (HR)-based genome editing strategy for correcting MECP2 mutations.
To assess the durability and precision of HR-based genome editing in Rett syndrome models.
To restore wild-type MECP2 expression while preserving native regulatory elements.

Main Methods:

Utilized stem cell-derived AAVHSCs for HR-based genome editing.
Designed an AAVHSC MECP2 editing vector homologous to the target MECP2 region.
Tested editing in Rett cell lines with mutations in MECP2 Exons 3 and 4.

Main Results:

Demonstrated successful and accurate correction of MECP2 mutations in Exons 3 and 4 in all analyzed Rett cell lines.
Observed rescue of MECP2 gene expression post-editing.
Mapped HR crossover events, confirming successful correction when mutations were flanked by crossovers.

Conclusions:

Nuclease-free HR-based genome editing effectively corrects MECP2 mutations in Rett syndrome models.
This strategy offers a potentially durable solution for Rett syndrome gene therapy by editing the genome directly.
The approach successfully restored MECP2 expression, highlighting its therapeutic potential.